Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 4
2017 3
2018 5
2019 10
2020 10
2021 11
2022 10
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Mitochondrial Haplogroups and Weight Gain After Initiating ART in Patients with HIV.
Berenguer J, Jarrín I, Bellón JM, Díez C, Jiménez-Sousa MA, López JC, Pinto-Martínez A, Moreno S, Montes ML, Iribarren JA, Orviz E, Portilla J, Villarroya F, Domingo P, Resino S; CoRIS cohort. Berenguer J, et al. J Infect Dis. 2024 Apr 1:jiae168. doi: 10.1093/infdis/jiae168. Online ahead of print. J Infect Dis. 2024. PMID: 38557859
Patterns of Sexualized Drug Use among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV: Insights from a Comprehensive Study-The U-SEX-2 GESIDA 9416 Study.
Ryan P, Dolengevich-Segal H, Ramos-Ruperto L, Cabello A, Sanchez-Conde M, Vergas J, Valencia J, Cuevas G, Sanz J, Curto-Ramos J, Pérez-Bootello J, Naharro-Rodriguez J, Ollero MJF, Garcia Fraile L, Pérez-Latorre L, Bisbal O, De la Fuente S, Losa JE, Cervero M, Estebanez M, Suarez-Garcia I, Gimeno A, Terrancle I, Mican R, González-Baeza A; U-Sex Gesida 9416 Study. Ryan P, et al. Among authors: bisbal o. J Clin Med. 2023 Nov 24;12(23):7293. doi: 10.3390/jcm12237293. J Clin Med. 2023. PMID: 38068345 Free PMC article.
Recently acquired hepatitis C: Epidemiological characteristics and treatment response in a large cohort of MSM living with HIV in Madrid.
Martín-Carbonero L, Gutierrez Á, Bisbal O, Vergas J, González-Baeza A, Rodríguez Martín C, Vivancos MJ, Sanz J, Álvarez B, Palomar M, de Los Santos I, Sepúlveda-Crespo D, Resino S, Berenguer J, Cano-Smith J, González-García J, Ryan P. Martín-Carbonero L, et al. Among authors: bisbal o. Enferm Infecc Microbiol Clin (Engl Ed). 2023 Nov 7:S2529-993X(23)00258-7. doi: 10.1016/j.eimce.2023.06.011. Online ahead of print. Enferm Infecc Microbiol Clin (Engl Ed). 2023. PMID: 37945463
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice.
Suárez-García I, Alejos B, Hernando V, Viñuela L, Vera García M, Rial-Crestelo D, Pérez Elías MJ, Albendín Iglesias H, Peraire J, Tiraboschi J, Díaz A, Moreno S, Jarrín I; Cohort of the Spanish HIV/AIDS Research Network (CoRIS). Suárez-García I, et al. J Antimicrob Chemother. 2023 Jun 1;78(6):1423-1432. doi: 10.1093/jac/dkad102. J Antimicrob Chemother. 2023. PMID: 37099559 Free PMC article.
Long-term evolution in liver disease markers and immune and lipid profiles in vertically HIV/HCV-coinfected youths with sustained viral response after direct-acting antivirals therapy.
Tarancon-Diez L, Carrasco I, Jiménez de Ory S, Berzosa Sánchez A, Hernanz-Lobo A, Montero-Alonso M, Laguno M, Bernardino JI, López-Cortés L, Aldamiz-Echevarría T, Collado P, Bisbal O, Samperiz G, Gavilán C, Ríos MJ, Ibarra S, Navarro ML, Muñoz-Fernández MÁ. Tarancon-Diez L, et al. Among authors: bisbal o. Biomed Pharmacother. 2023 Jun;162:114587. doi: 10.1016/j.biopha.2023.114587. Epub 2023 Mar 30. Biomed Pharmacother. 2023. PMID: 37003032 Free article.
Corrigendum to "Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)".
De Miguel R, Rial-Crestelo D, Dominguez-Dominguez L, Montejano R, Esteban-Cantos A, Aranguren-Rivas P, Stella-Ascariz N, Bisbal O, Bermejo-Plaza L, Garcia-Alvarez M, Alejos B, Hernando A, Santacreu-Guerrero M, Cadiñanos J, Mayoral M, Castro JM, Moreno V, Martin-Carbonero L, Delgado R, Rubio R, Pulido F, Arribas JR; ART-PRO, PI16/00837-PI16/00678 study group. De Miguel R, et al. Among authors: bisbal o. EBioMedicine. 2023 Mar;89:104486. doi: 10.1016/j.ebiom.2023.104486. Epub 2023 Feb 18. EBioMedicine. 2023. PMID: 36806001 Free PMC article. No abstract available.
Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance.
De Miguel Buckley R, Rial-Crestelo D, Montejano R, Pinto A, Jimenez-Gonzalez M, Lagarde M, Esteban-Cantos A, Aranguren-Rivas P, Cadiñanos J, Bisbal O, Castro JM, Santacreu-Guerrero M, Bermejo-Plaza L, Moreno V, Hernando A, Martín-Carbonero L, Rubio R, Delgado R, Arribas JR, Pulido F; Antiretroviral Treatment Guided by Proviral Genotype (ART-PRO) Study Group. De Miguel Buckley R, et al. Among authors: bisbal o. Open Forum Infect Dis. 2022 Nov 8;9(11):ofac610. doi: 10.1093/ofid/ofac610. eCollection 2022 Nov. Open Forum Infect Dis. 2022. PMID: 36447613 Free PMC article.
Use of Tenofovir Alafenamide/Emtricitabine/Elvitegravir-Cobicistat in HIV-Naive Patients with Advanced Disease: GENIS Study.
Perez Stachowski J, Rial Crestelo D, Moreno Zamora A, Cabello N, Ryan P, Espinosa Aguilera N, Bisbal O, Vivancos Gallego MJ, Nuñez MJ, Troya J, Dominguez M, Sierra JO. Perez Stachowski J, et al. Among authors: bisbal o. J Clin Med. 2022 Aug 25;11(17):4994. doi: 10.3390/jcm11174994. J Clin Med. 2022. PMID: 36078925 Free PMC article.
57 results